Symbiosis Builds Global Business Development Strength with Two North American Appointments

Stirling, UK – 28 October 2025 – Symbiosis Pharmaceutical Services (Symbiosis), a global contract manufacturing organisation (CMO) specialising in the sterile manufacture of injectable drug products, has strengthened its business development team in the US with the dual appointments of Kevin O’Brien and LeeAnn Nguyen as Vice Presidents of Business Development for North America, and North America and Asia respectively. 

With over 30 years of experience in the pharmaceutical industry, Kevin brings extensive experience in client development and a strong technical background. Prior to joining Symbiosis, he served as Vice President of Business Development at Siegfried, representing multiple drug manufacturing sites. Based in California, Kevin’s focus will be to drive client growth and promote awareness of Symbiosis’ specialist sterile manufacturing capabilities across North America, 

Commenting on his new role, Kevin said: “Symbiosis is an established yet agile CMO and the company’s ability to react quickly to client needs is what truly sets it apart. My focus will be to use my industry relationships and experience to increase Symbiosis’ visibility in the US, attract new projects and identify opportunities for expanding our capabilities in response to evolving market needs.”

LeeAnn Nguyen joins the company with more than 15 years of experience in the life sciences industry. Most recently, LeeAnn was Director of Business Development at Ajinomoto Biopharma Services where she focused on supporting clients through complex sterile manufacturing programs. Based in Raleigh, North Carolina, LeeAnn will focus on securing new clinical and commercial partnerships and positioning Symbiosis as a trusted partner for companies seeking accelerated project timelines. 

LeeAnn said: “I was drawn to Symbiosis because of their global reputation for excellence in sterile fill/finish manufacturing. Symbiosis also stands out by being able to bring drug manufacturing projects online in as little as 8-12 weeks. That level of responsiveness is rare in an industry often constrained by capacity and is highly valued by clients. I’m excited to contribute to that responsiveness and help strengthen our partnerships worldwide.”

Colin MacKay, Chief Executive Officer at Symbiosis, said: “We’re delighted to welcome Kevin and LeeAnn to the Symbiosis team at what is an exciting time for the company. With our recently expanded manufacturing capacity, their extensive experience, client focus, and strong networks in the North American and Asian markets will be instrumental in Symbiosis continued global expansion. These appointments reinforce the company’s ongoing commitment to providing fast, flexible, high-quality sterile manufacturing solutions for our clients.”

With expanded commercial leadership across North America, Symbiosis continues to strengthen its position as a leading global CMO, providing biopharmaceutical innovators with rapid, reliable, and regulatory compliant access to sterile manufacturing capacity.

ENDS

About Symbiosis Pharmaceutical Services
Symbiosis Pharmaceutical Services (Symbiosis) is a world-class Contract Manufacturing Organisation (CMO) located in Stirling, UK, and is a specialist sterile GMP manufacturer of biopharmaceuticals for use in clinical trials and commercial sales globally. Symbiosis is MHRA-licensed and FDA-inspected and offers a range of services including the aseptic fill/finish of medicines into vials, analytical testing, QP release of product, inspection, labelling, packaging and GMP temperature-controlled storage and shipment of medicines. 

The Symbiosis facilities in Stirling, Scotland, were designed for biologic and small molecule pharmaceutical production to support biotechnology and pharmaceutical companies worldwide requiring sterile injectable pharmaceutical products manufactured in short timeframes for clinical trial use and commercial supply.

Regulatory compliance, technical capability and operational flexibility are core to the Symbiosis value proposition along with direct access to a highly experienced team of life science experts. By adding value directly to the new drug development projects and the commercial manufacturing supply chain requirements of its clients, Symbiosis has demonstrated consistent annual growth and built long-term relationships with its client base globally.

For more information on Symbiosis visit http://www.symbiosis-pharma.com or follow us on LinkedIn.

Media Contact:
Rachael Heath
ramarketing
rachael@ramarketingpr.com
www.ramarketingpr.com